[go: up one dir, main page]

WO2008000950A3 - Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique - Google Patents

Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique Download PDF

Info

Publication number
WO2008000950A3
WO2008000950A3 PCT/FR2007/001069 FR2007001069W WO2008000950A3 WO 2008000950 A3 WO2008000950 A3 WO 2008000950A3 FR 2007001069 W FR2007001069 W FR 2007001069W WO 2008000950 A3 WO2008000950 A3 WO 2008000950A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
ureas
pyrrolidine
piperidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/001069
Other languages
English (en)
Other versions
WO2008000950A2 (fr
Inventor
Alain Braun
Stefan Gussregen
Patrick Mougenot
Claudie Namane
Eric Nicolai
Francois Pacquet
Christophe Philippo
Olivier Venier
Olivier Crespin
Cecile Pascal
Michel Aletru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0605786A external-priority patent/FR2902790A1/fr
Priority to BRPI0713042-2A priority Critical patent/BRPI0713042A2/pt
Priority to CA002652852A priority patent/CA2652852A1/fr
Priority to MX2008016563A priority patent/MX2008016563A/es
Priority to EP07803781A priority patent/EP2044057A2/fr
Priority to JP2009517318A priority patent/JP2009541463A/ja
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to AU2007264791A priority patent/AU2007264791A1/en
Publication of WO2008000950A2 publication Critical patent/WO2008000950A2/fr
Publication of WO2008000950A3 publication Critical patent/WO2008000950A3/fr
Priority to IL195820A priority patent/IL195820A0/en
Priority to US12/337,967 priority patent/US7947834B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des composés répondant à la formule (I): dans laquelle R1a, R1b, R 1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b, R4, n, j, j, o, p, q, r et X sont tels que définis dans la description et leur utilisation comme modulateurs de la 11 β- hydroxystéroïde déhydrogénase de type 1 pour le traitement du syndrome métabolique ou du diabète de type 2.
PCT/FR2007/001069 2006-06-27 2007-06-26 Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique Ceased WO2008000950A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2007264791A AU2007264791A1 (en) 2006-06-27 2007-06-26 Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
CA002652852A CA2652852A1 (fr) 2006-06-27 2007-06-26 Derives d'urees de piperidine ou pyrrolidine, leur preparation et leur application en therapeutique
MX2008016563A MX2008016563A (es) 2006-06-27 2007-06-26 Derivados de ureas de piperidina o pirrolidina, su preparación y su aplicación en terapeutica.
EP07803781A EP2044057A2 (fr) 2006-06-27 2007-06-26 Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique
JP2009517318A JP2009541463A (ja) 2006-06-27 2007-06-26 ピペリジンまたはピロリジンの尿素誘導体、これらの調製およびこれらの治療的使用
BRPI0713042-2A BRPI0713042A2 (pt) 2006-06-27 2007-06-26 derivados de urÉias de piperidina ou pirrolidina, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
IL195820A IL195820A0 (en) 2006-06-27 2008-12-09 Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
US12/337,967 US7947834B2 (en) 2006-06-27 2008-12-18 Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0605786 2006-06-27
FR0605786A FR2902790A1 (fr) 2006-06-27 2006-06-27 Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique
FR0611239 2006-12-22
FR0611239 2006-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/337,967 Continuation US7947834B2 (en) 2006-06-27 2008-12-18 Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators

Publications (2)

Publication Number Publication Date
WO2008000950A2 WO2008000950A2 (fr) 2008-01-03
WO2008000950A3 true WO2008000950A3 (fr) 2008-02-14

Family

ID=38692075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001069 Ceased WO2008000950A2 (fr) 2006-06-27 2007-06-26 Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique

Country Status (16)

Country Link
US (1) US7947834B2 (fr)
EP (1) EP2044057A2 (fr)
JP (1) JP2009541463A (fr)
KR (1) KR20090021192A (fr)
AR (1) AR061643A1 (fr)
AU (1) AU2007264791A1 (fr)
BR (1) BRPI0713042A2 (fr)
CA (1) CA2652852A1 (fr)
CL (1) CL2007001886A1 (fr)
IL (1) IL195820A0 (fr)
MX (1) MX2008016563A (fr)
PE (1) PE20080212A1 (fr)
RU (1) RU2009102527A (fr)
TW (1) TW200811158A (fr)
UY (1) UY30448A1 (fr)
WO (1) WO2008000950A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4401428B2 (ja) 2006-06-27 2010-01-20 武田薬品工業株式会社 縮合環化合物
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
FR2948369B1 (fr) 2009-07-27 2013-04-12 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR2948370B1 (fr) * 2009-07-27 2013-04-05 Sanofi Aventis Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
PT3071203T (pt) 2013-11-18 2021-03-11 Forma Therapeutics Inc Composições de tetra-hidroquinolina como inibidores de bromodomínio bet
CA3217690A1 (fr) * 2021-05-07 2022-11-10 Tero Linnanen Nouveaux composes heterocycliques, compositions, procedes de preparation et utilisations de ceux-ci
EP4538270A4 (fr) * 2022-06-10 2025-07-02 Sapiensbio Inc Nouveau composé et composition pharmaceutique le comprenant en tant que principe actif

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022552A1 (fr) * 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
EP1283199A1 (fr) * 2000-05-16 2003-02-12 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2003031436A1 (fr) * 2001-10-05 2003-04-17 Recordati S.A. Composes heterocycliques utilises pour traiter des troubles de la voie urinaire
WO2004033427A1 (fr) * 2002-10-11 2004-04-22 Astrazeneca Ab Derives de piperidine 1,4 disubstituee et leur utilisation en tant qu'inhibiteurs de 11-betahsd1
WO2005047250A1 (fr) * 2003-11-05 2005-05-26 Astrazeneca Ab Utilisation de 3-(benzoyl)-pyrrolidines n-acylees comme inhibiteurs de 11-beta-hsdi pour le traitement de troubles metaboliques
WO2006053024A2 (fr) * 2004-11-10 2006-05-18 Incyte Corporation Composes de lactame et leur utilisation en temps que substances pharmaceutiques
WO2006055752A2 (fr) * 2004-11-18 2006-05-26 Incyte Corporation INHIBITEURS DE LA 11-β-HYDROXYSTEROIDE DEHYDROGENASE DE TYPE 1 ET PROCEDES D’UTILISATION
WO2006105127A2 (fr) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Inhibiteurs de l'hydroxysteroide deshydrogenase
WO2006132436A1 (fr) * 2005-06-08 2006-12-14 Japan Tobacco Inc. Composé hétérocyclique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE38835T1 (de) 1983-07-05 1988-12-15 Pfizer Karbonsaeure-derivate verwendbar bei der verhuetung der zersetzung von knorpeln.
US6369057B1 (en) * 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
EP1615698B1 (fr) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC Nouvelles amides substitues et leur utilisation pharmaceutique

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022552A1 (fr) * 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
EP1283199A1 (fr) * 2000-05-16 2003-02-12 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2003031436A1 (fr) * 2001-10-05 2003-04-17 Recordati S.A. Composes heterocycliques utilises pour traiter des troubles de la voie urinaire
WO2004033427A1 (fr) * 2002-10-11 2004-04-22 Astrazeneca Ab Derives de piperidine 1,4 disubstituee et leur utilisation en tant qu'inhibiteurs de 11-betahsd1
WO2005047250A1 (fr) * 2003-11-05 2005-05-26 Astrazeneca Ab Utilisation de 3-(benzoyl)-pyrrolidines n-acylees comme inhibiteurs de 11-beta-hsdi pour le traitement de troubles metaboliques
WO2006053024A2 (fr) * 2004-11-10 2006-05-18 Incyte Corporation Composes de lactame et leur utilisation en temps que substances pharmaceutiques
WO2006055752A2 (fr) * 2004-11-18 2006-05-26 Incyte Corporation INHIBITEURS DE LA 11-β-HYDROXYSTEROIDE DEHYDROGENASE DE TYPE 1 ET PROCEDES D’UTILISATION
WO2006105127A2 (fr) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Inhibiteurs de l'hydroxysteroide deshydrogenase
WO2006132436A1 (fr) * 2005-06-08 2006-12-14 Japan Tobacco Inc. Composé hétérocyclique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRZYB J A ET AL: "Carbamoylimidazolium and thiocarbamoylimidazolium salts: novel reagents for the synthesis of ureas, thioureas, carbamates, thiocarbamates and amides", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 61, no. 30, 25 July 2005 (2005-07-25), pages 7153 - 7175, XP004970475, ISSN: 0040-4020 *

Also Published As

Publication number Publication date
US20090176775A1 (en) 2009-07-09
PE20080212A1 (es) 2008-04-25
TW200811158A (en) 2008-03-01
AR061643A1 (es) 2008-09-10
CL2007001886A1 (es) 2009-11-10
US7947834B2 (en) 2011-05-24
RU2009102527A (ru) 2010-08-10
UY30448A1 (es) 2008-01-31
BRPI0713042A2 (pt) 2013-01-08
WO2008000950A2 (fr) 2008-01-03
IL195820A0 (en) 2009-09-01
JP2009541463A (ja) 2009-11-26
CA2652852A1 (fr) 2008-01-03
KR20090021192A (ko) 2009-02-27
MX2008016563A (es) 2009-03-02
EP2044057A2 (fr) 2009-04-08
AU2007264791A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
WO2008000950A3 (fr) Dérivés d'urées de piperidine ou pyrrolidine, leur préparation et leur application en thérapeutique
WO2008000951A3 (fr) Dérivés d'urees de tropane, leur préparation et leur application en thérapeutique
IL184722A0 (en) Novel haloalkylsulfonanilide derivative, herbicide, and method of use thereof
TWI365866B (en) Amide derivatives, process for preparation thereof and use thereof as insecticide
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
EP1783110A4 (fr) Nouveau derive de cyclohexane, promedicament et sel de derive de cyclohexane, et agent therapeutique contenant ce derive pour traitement du diabete
SI1931660T1 (sl) Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
IL196586A0 (en) Substituted spiroketal derivatives and use thereof as therapeutic drug for diabetes
WO2007087431A3 (fr) Pulvérisation sublinguale de fentanyle
ZA200801629B (en) Phenyl - and pyridinyl - 1, 2, 4 - oxadiozolone derivatives, processes for their preparation and their use as pharmaceuticals
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
IL179424A0 (en) Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
PL1928836T3 (pl) Podstawione 4-fenylotetrahydroizochinoliny, sposób ich wytwarzania, zastosowanie jako lek oraz lek je zawierający
IL190519A0 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
EP1968616A4 (fr) Dérivés du sulindac, utilisation et préparation de ces derniers
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
IL190230A0 (en) Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
IL191892A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ATE411295T1 (de) 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung
ATE441643T1 (de) N-ä(4,5-diphenylpyrimidin-2- yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
DE602004012275D1 (de) zu dessen Herstellung und Impstoffderivate davon
EP2119700A4 (fr) Dérivé de benzylamine ou sel d'addition avec un acide acceptable du point de vue pharmaceutique de celui-ci et utilisation de ceux-ci à des fins médicales
TH92860A (fr)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780024556.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803781

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2652852

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 195820

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5196/KOLNP/2008

Country of ref document: IN

Ref document number: MX/A/2008/016563

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007803781

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009517318

Country of ref document: JP

Ref document number: 1020087031622

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007264791

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009102527

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007264791

Country of ref document: AU

Date of ref document: 20070626

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0713042

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081229